Gefapixant Availability in India
Gefapixant is NOT currently available in India. The drug has received regulatory approval in several countries including Japan, Switzerland, and the European Union for treatment of refractory or unexplained chronic cough, but it has not been approved by India's Central Drugs Standard Control Organisation (CDSCO) as of current evidence.
Current Regulatory Status
Based on the available evidence, gefapixant's approval status is limited to specific markets:
- Approved markets: The drug has gained approval in multiple countries for chronic cough treatment 1
- India-specific status: No evidence in the provided literature indicates approval or availability in India
- Access pathway: Indian patients would need to explore compassionate use programs or medical tourism to access gefapixant, as it is not commercially available domestically
Clinical Context for Indian Practitioners
If you are managing a patient with refractory chronic cough in India, gefapixant is not a treatment option you can prescribe locally. The evidence shows gefapixant is effective for chronic cough, with:
- Efficacy: 28.1% reduction in 24-hour cough frequency at therapeutic doses (90.7 mg/day ED50) 2
- Real-world response: 50% of patients report meaningful improvement (≥5/10 response rate), with 25% reporting excellent response (≥8/10) 3
- Rapid onset: Improvement typically seen within 2 weeks in responders 3
However, the drug carries significant tolerability concerns:
- Taste disturbances: 38% absolute risk increase for dysgeusia/hypogeusia, which is dose-dependent 2
- Discontinuation: Higher rates due to taste-related adverse effects 2
Alternative Management in India
Since gefapixant is unavailable, focus on evidence-based alternatives for refractory chronic cough:
- GERD-directed therapy: Intensive medical regimen including PPIs, prokinetic agents, and dietary modifications (≤45g fat/day, avoiding coffee, tea, alcohol, chocolate, citrus) 4
- Treatment duration: Medical therapy for GERD-related cough improves symptoms in 70-100% when not limited to acid suppression alone 4
- Surgical option: Anti-reflux surgery improves cough in approximately 85% of patients who fail intensive medical therapy 4
Monitor regulatory updates from CDSCO for potential future approval of gefapixant in India.